Financing opportunities from China: targeting investors and shaping deals
Join us for the second meeting of the China SIG, where we will gain practical advice around obtaining investment from China, and hear some shared experiences from those who have done it before.
The China Biotech SIG has been set up with the China-Britain Business Council (CBBC), and supported by the Department for International Trade (DIT), to provide a discussion platform for BIA and CBBC members in the Biotech sector, exploring the opportunities for business growth in and with China, via trade and investment.
The group is open to BIA and CBBC members only. The event is free of charge, however please register as there is limited capacity.
Dr Jonathan Tobin
Jonathan specialises in biotechnology investments. He currently sits on the board of Artios Pharma. Prior to joining Arix Bioscience, Jonathan spent five years at Imperial Innovations, where he was a Principal in the Healthcare Ventures team. He was involved with the formation and investment in a number of early stage companies, including Inivata, Auspherix, Abingdon Health, Cell Medica, and Psioxus. Jonathan also worked at MRC Technology, sourcing and evaluating new small molecule and antibody drug discovery projects.
He has a first class degree in biology from the University of Oxford, a PhD in Molecular Medicine from UCL, carried out postdoctoral research at the Cancer Research UK London Research Institute (now Crick Institute), and published research in journals including PNAS, New England Journal of Medicine, and Nature Genetics. Jonathan also has an MBA with distinction from Imperial College, and is a Trustee of the Autism Research Trust.
Tim is an experienced corporate communicator with a strong background in science communication, branding and positioning, international B2B communications, and reputation management. His focus is life sciences clients, including biotech startups, biomedical research charities, and tools and technology providers. He previously worked at The Royal Society, the British Science Association, and the National Centre for the 3Rs in Animal Research.
Neil Clark, CEO, has broad experience within private and public biotechnology and healthcare companies at CEO and CFO level. Neil has been successful in completing two previous London listings, a SEC acquisition and several secondary financings. Neil has also been involved in identifying and completing licensing deals with pharma and biotech companies and managing international business development projects in healthcare.
Joyce is a Director at IP Group, UK’s largest intellectual property commercialisation company. She focuses on capital market transactions and fund management business at IP Group, and leads the group’s China connectivity efforts. At IP Group she has led a number of significant transactions with Chinese investors’ participation. Prior to IP Group, she worked in M&A advisory at HSBC’s investment banking division covering the Telecoms, Media, and Technology sector. Prior to investment banking, Joyce worked as an investment manager, managing discretionary portfolios for Ultra High Net Worth clients at HSBC Private Bank. Joyce has worked in London, New York, Hong Kong, and Paris, and speaks fluently English, French, and Mandarin. Joyce is a CFA charterholder and holds a Master’s degree in Finance from ESCP Europe.
Arnold and Porter
International Financial Centre
25 Old Broad St
Lincoln Tsang, Arnold and Porter
Practical advice around investment from China
15.40 China Capital Market and the Chinese perspective
Joyce Xie, IP Capital, IP Group
15.55 How to send the right message in China
Tim Watson, Associate Partner, Instinctif Partners
Lessons learned from deals made
16.10 Strategic agreements and collaboration
Jonathan Tobin, Investment Director, Arix Bioscience
16.25 Chinese investment for drug development
Neil Clark, CEO, Destiny Pharma
Discussion and Q&A
16.40 Q&A with all the speakers
17.00 Drinks and networking